Mostrar el registro sencillo del ítem
dc.contributor.author | Pastor-Ibáñez, Roque | |
dc.contributor.author | Díez-Fuertes, Francisco | |
dc.contributor.author | Sánchez-Palomino, Sonsoles | |
dc.contributor.author | Alcamí, José | |
dc.contributor.author | Plana, Montserrat | |
dc.contributor.author | Torrents, David | |
dc.contributor.author | Leal, Lorna | |
dc.contributor.author | García, Felipe | |
dc.date.accessioned | 2022-04-08T12:02:22Z | |
dc.date.available | 2022-04-08T12:02:22Z | |
dc.date.issued | 2021-06-24 | |
dc.identifier.citation | Vaccines (Basel). 2021;9(7):694 | es_ES |
dc.identifier.issn | 2076-393X | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/13978 | |
dc.description.abstract | Therapeutic vaccines based on dendritic cells offer a good approach to HIV-specific T-cell responses and partial control of the viral load after antiretroviral therapy interruption. The aim of the present study was to identify mRNA expression profiles and to assess the impact of the gut microbiome composition for predicting the viral load control after antiretroviral therapy interruption. We enrolled 29 patients to receive either placebo or a monocyte-derived dendritic cell vaccine. Patients with a decrease in their viral load of >0.5 log10 copies/mL by 12 weeks after antiretroviral therapy interruption were considered responders. In total, 66 genes were considered differentially expressed between responders and non-responders. Enrichment analysis revealed several upregulated pathways involved in the host defense response to a virus via the type I interferon signaling pathway. Regarding the gut microbiota, responders showed enriched levels of Bacteroidetes (p < 0.005) and Verrucomicrobia (p = 0.017), while non-responders were enriched with Tenericutes (p = 0.049) and Actinobacteria (p < 0.005). We also found important differences at the genus level. However, we did not discover any effect of the dendritic cell vaccine on the transcriptome or the gut microbiota. An alternative analysis did characterize that the microbiota from responders were associated with the metabolic production of short-chain fatty acids, which are key metabolites in the regulation of intestinal homeostasis. The evidence now consistently shows that short-chain fatty acid depletion occurs in HIV-infected individuals receiving antiretroviral treatment. | es_ES |
dc.description.sponsorship | This study was partially supported by the SPANISH AIDS Research Network (RIS) projects RD16/0025/0002 and RD16/0025/0013 integrated in the State Plan for Scientific and Technical Research and Innovation from the General Sub-Directorate for research assessment and promotion; Spanish Carlos III Institute of Health (ISCIII) co-funded by the European Regional Development Fund (FEDER); the Fondo de Investigación Sanitaria (FIS), AC16/00051 and PI18/00699; Gilead grants in Biomedical research in HIV, hepatic, and hemo-oncology from the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R and RTI2018-096309-B-I00); and the income found from Europe in the Regional Development (FEDER) and the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653. Felipe García received the support of José María Segovia de Arana contracts. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | HIV-1 | es_ES |
dc.subject | Antiretroviral | es_ES |
dc.subject | Dendritic cell | es_ES |
dc.subject | Microbiota | es_ES |
dc.subject | Transcriptomics | es_ES |
dc.subject | Vaccine | es_ES |
dc.title | Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 34202658 | es_ES |
dc.format.volume | 9 | es_ES |
dc.format.number | 7 | es_ES |
dc.format.page | 694 | es_ES |
dc.identifier.doi | 10.3390/vaccines9070694 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Red de Investigación Cooperativa en Investigación en Sida (España) | es_ES |
dc.contributor.funder | Ministerio de Economía (España) | es_ES |
dc.contributor.funder | Gilead Sciences (Spain) | es_ES |
dc.contributor.funder | Government of Catalonia (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.relation.publisherversion | https://doi.org/10.3390/vaccines9070694 | es_ES |
dc.identifier.journal | Vaccines | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0002/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0013/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//SAF2015-66193-R/ES/UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA INMUNOGENICIDAD Y EFICACIA DE VACUNAS TERAPEUTICAS FRENTE A VIH/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RTI2018-096309-B-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//AC16%2F00051/ES/Diseño de vacunas frente a la gripe humana mediante micelas multifuncionales capaces de utilizar la inmunidad innata/ | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18 - Proyectos de investigacion en salud (AES 2018). Modalidad proyectos en salud. (2018)/PI18/00699 | es_ES |